Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
NCT06657209
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetes Mellitus, Type 2
- Diabetes
- Type 2 Diabetes
- Pre Diabetes
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Stanford University
- Last updated on ClinicalTrials.gov
- April 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford University · Palo Alto, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.